Brought to you by 
Elixir grants Novartis option on development programs
05 Nov 2007
Executive Summary
Elixir Pharmaceuticals has granted Novartis AG an option to acquire development and commercialization rights to either its ghrelin agonist candidate (in-licensed in 2005 from Bristol-Myers Squibb) or one of its sirtuin (SIRT) programs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elixir grants Novartis option on development programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice